Author

Carl Eriksson

LONG-TERM OUTCOMES OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE - THE SWEDISH PROSPECTIVE MULTICENTRE SVEAH EXTENSION STUDY
LONG-TERM OUTCOMES OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE - THE SWEDISH PROSPECTIVE MULTICENTRE SVEAH EXTENSION STUDY

Carl Eriksson  et al.

REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER
REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER

Carl Eriksson  et al.

THE ROAD TO AND SEQUENCE OF BIOLOGICAL THERAPY IN A POPULATION-BASED, EUROPEAN INCEPTION COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE -AN EPI-IBD COHORT STUDY
THE ROAD TO AND SEQUENCE OF BIOLOGICAL THERAPY IN A POPULATION-BASED, EUROPEAN INCEPTION COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE -AN EPI-IBD COHORT STUDY

Carl Eriksson  et al.

DISEASE COURSE OF CROHN’S DISEASE DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT
DISEASE COURSE OF CROHN’S DISEASE DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT

Carl Eriksson  et al.

DISEASE COURSE OF ULCERATIVE COLITIS DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT
DISEASE COURSE OF ULCERATIVE COLITIS DURING THE FIRST TEN YEARS FOLLOWING DIAGNOSIS IN A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT – THE EPI-IBD COHORT

Carl Eriksson  et al.

EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY
EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

Carl Eriksson  et al.

Item 1 - 6 / 6
1